Phio Pharmaceuticals Corp, a company operating within the Health Care sector and specializing in the Biotechnology industry, recently disclosed its financial results for the second quarter of 2026, alongside a comprehensive business update. The company, which is publicly traded on the Nasdaq stock exchange, focuses on cancer immunotherapy and the development of medications for various diseases, primarily serving the United States market.
In its latest financial report, Phio Pharmaceuticals Corp highlighted significant advancements concerning its lead clinical candidate, PH-762. The company has initiated commercial-scale active pharmaceutical ingredient (API) production, completed a long-term non-clinical toxicology study, and finalized the analysis of Phase 1b pharmacology data. These developments are pivotal as they are expected to inform the design of the forthcoming clinical trial.
Despite a decrease in cash and cash equivalents compared to the previous year, Phio Pharmaceuticals Corp maintains sufficient liquidity to support its operations through the second half of 2027. The company’s financial health is underscored by a market capitalization of $12,430,000 USD, with a close price of $1.06 as of August 5, 2026. The price-to-earnings ratio stands at -0.72, reflecting the company’s current financial performance.
The financial results also revealed a marked increase in research and development (R&D) expenses, primarily driven by elevated costs associated with non-clinical toxicology and chemistry-manufacturing-controls. Conversely, general and administrative expenses experienced a modest decline. These factors contributed to a widened net loss for the quarter, underscoring the company’s intensified focus on R&D.
In addition to its financial and operational updates, Phio Pharmaceuticals Corp announced an at-the-market equity offering. This strategic move is aimed at bolstering the company’s financial position. Furthermore, the company has strengthened its board by appointing a dermatologist with extensive FDA experience, enhancing its regulatory and strategic oversight capabilities.
As Phio Pharmaceuticals Corp continues to navigate the complexities of drug development and commercialization, these updates reflect its commitment to advancing its pipeline and maintaining operational stability. For more information, stakeholders are encouraged to visit the company’s official website at www.phiopharma.com .
